ALLO
Price
$1.51
Change
-$0.00 (-0.00%)
Updated
Jul 25, 04:24 PM (EDT)
Capitalization
363.09M
12 days until earnings call
SLDB
Price
$6.80
Change
+$0.12 (+1.80%)
Updated
Jul 25, 03:14 PM (EDT)
Capitalization
524M
Interact to see
Advertisement

ALLO vs SLDB

Header iconALLO vs SLDB Comparison
Open Charts ALLO vs SLDBBanner chart's image
Allogene Therapeutics
Price$1.51
Change-$0.00 (-0.00%)
Volume$14.53K
Capitalization363.09M
Solid Biosciences
Price$6.80
Change+$0.12 (+1.80%)
Volume$260
Capitalization524M
ALLO vs SLDB Comparison Chart in %
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. SLDB commentary
Jul 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Buy and SLDB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 25, 2025
Stock price -- (ALLO: $1.51 vs. SLDB: $6.68)
Brand notoriety: ALLO and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 138% vs. SLDB: 94%
Market capitalization -- ALLO: $363.09M vs. SLDB: $524M
ALLO [@Biotechnology] is valued at $363.09M. SLDB’s [@Biotechnology] market capitalization is $524M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 5 bearish.
  • SLDB’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ALLO and SLDB are a good buy in the short-term.

Price Growth

ALLO (@Biotechnology) experienced а +21.77% price change this week, while SLDB (@Biotechnology) price change was +15.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.80%. For the same industry, the average monthly price growth was +19.86%, and the average quarterly price growth was +29.58%.

Reported Earning Dates

ALLO is expected to report earnings on Oct 30, 2025.

SLDB is expected to report earnings on May 15, 2025.

Industries' Descriptions

@Biotechnology (+8.80% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($524M) has a higher market cap than ALLO($363M). SLDB YTD gains are higher at: 67.000 vs. ALLO (-29.108). SLDB has higher annual earnings (EBITDA): -136.83M vs. ALLO (-238.37M). SLDB has more cash in the bank: 307M vs. ALLO (280M). SLDB has less debt than ALLO: SLDB (23.6M) vs ALLO (81.3M). ALLO (0) and SLDB (0) have equivalent revenues.
ALLOSLDBALLO / SLDB
Capitalization363M524M69%
EBITDA-238.37M-136.83M174%
Gain YTD-29.10867.000-43%
P/E RatioN/AN/A-
Revenue00-
Total Cash280M307M91%
Total Debt81.3M23.6M344%
FUNDAMENTALS RATINGS
ALLO vs SLDB: Fundamental Ratings
ALLO
SLDB
OUTLOOK RATING
1..100
1861
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
5036
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (27) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that SLDB’s stock grew significantly faster than ALLO’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that SLDB’s stock grew similarly to ALLO’s over the last 12 months.

SLDB's SMR Rating (97) in the Biotechnology industry is in the same range as ALLO (97). This means that SLDB’s stock grew similarly to ALLO’s over the last 12 months.

SLDB's Price Growth Rating (36) in the Biotechnology industry is in the same range as ALLO (50). This means that SLDB’s stock grew similarly to ALLO’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ALLO (100). This means that SLDB’s stock grew significantly faster than ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOSLDB
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BMBN29.000.25
+0.87%
Benchmark Bankshares, Inc.
ELMUY27.10N/A
N/A
Elisa Communications Corp.
SDCVF63.03N/A
N/A
Sa des Ciments Vicat
CLOQ0.12N/A
-0.08%
Cyberloq Technologies Inc.
PPRUY24.68-0.83
-3.25%
Kering SA